首页 | 本学科首页   官方微博 | 高级检索  
     

表皮生长因子受体和整合素通路交叉作用对胃癌细胞侵袭的影响
引用本文:丁健,李丹,林纳,王小众,王承党,吴婷. 表皮生长因子受体和整合素通路交叉作用对胃癌细胞侵袭的影响[J]. 第三军医大学学报, 2012, 34(1): 34-38
作者姓名:丁健  李丹  林纳  王小众  王承党  吴婷
作者单位:丁健 (福建医科大学附属第一医院消化内科,福州,350005) ; 李丹 (福建医科大学附属协和医院消化内科,福州,350001) ; 林纳 (福建医科大学附属协和医院消化内科,福州,350001) ; 王小众 (福建医科大学附属协和医院消化内科,福州,350001) ; 王承党 (福建医科大学附属第一医院消化内科,福州,350005) ; 吴婷 (福建医科大学附属第一医院消化内科,福州,350005) ;
基金项目:福建省自然科学基金,福建省卫生厅创新基金,福建医科大学苗圃科研基金
摘    要:目的了解表皮生长因子受体(epidermal growth factor receptor,EGFR)和整合素信号通路在胃癌细胞SGC7901中的交叉反应和对细胞侵袭增殖的影响。方法使用EGF和Fn刺激SGC7901细胞,免疫沉淀和蛋白质电泳检测ERK、FAK和p130cas总蛋白和FAK Y397、p130cas Y410和ERK总酪氨酸磷酸化的改变;使用改良Boyden小室法检测胃癌细胞侵袭力;MTT法检测细胞增殖的改变;使用RNA干扰降低FAK表达,观察FAK低表达对交叉反应和胃癌侵袭增殖的影响。结果 ERK、FAK和p130cas总蛋白在刺激前后无变化(P>0.05)。Fn刺激后,ERK总酪氨酸磷酸化增强了2.90倍(P<0.05),细胞侵袭力增强了2.36倍(P<0.05),24 h MTT值升高了1.68倍(P<0.05);EGF刺激后,FAKY397磷酸化增强了2.75倍(P<0.05),p130cas Y410磷酸化增强了4.33倍(P<0.05),细胞侵袭力增强了1.50倍(P<0.05),24 h MTT值分别升高了1.76倍(P<0.05)。转染FAK siRNA组细胞,FAK Y397磷酸化表达只有对照组的0.30倍(P<0.05);Fn刺激后,ERK总磷酸化表达只有对照组的0.66倍(P<0.05),细胞侵袭力只有对照组的0.37倍(P<0.05),24 h MTT值只有对照组的0.63倍(P<0.05);EGF刺激后,p130 Y410磷酸化只有对照组的0.49倍(P<0.05),细胞侵袭力只有对照组的0.48倍(P<0.05),24 h MTT值只有对照组0.77倍(P<0.05)。结论 EGFR和整合素信号在胃癌细胞中发生交叉反应,FAK是其中的关键信号分子,阻断FAK表达可以有效抑制两条信号通路引起的胃癌细胞侵袭和增殖。

关 键 词:胃癌  表皮生长因子受体  整合素  交叉反应  侵袭

Effect of crosstalk between EGFR and integrin signaling pathways on invasion of gastric cancer cells
Ding Jian,Li Dan,Lin Na,Wang Xiaozhong,Wang Chengdang,Wu Ting. Effect of crosstalk between EGFR and integrin signaling pathways on invasion of gastric cancer cells[J]. Acta Academiae Medicinae Militaris Tertiae, 2012, 34(1): 34-38
Authors:Ding Jian  Li Dan  Lin Na  Wang Xiaozhong  Wang Chengdang  Wu Ting
Affiliation:1(1Department of Enterology,First Affiliated Hospital,Fujian Medical University,Fuzhou,Fujian Province,350005;2Department of Enterology,Union Hospital of Fujian Medical University,Fuzhou,Fujian Province,350001,China)
Abstract:Objective To understand crosstalk between epidermal growth factor receptor(EGFR) and integrin signaling pathways and effect of the crosstalk on cell invasion and proliferation in human gastric cancer cell SGC7901.Methods Human gastric cancer cells SGC7901 were stimulated with EGF and Fn,respectively.Protein expressions of total and phosphorylated ERK,FAK(Y397) and p130cas(Y410) were measured by immunoprecipitation and Western blotting.Invasion and proliferation of gastric cancer cells were detected by modified Boyden chamber and MTT assay.RNA interference was used to block FAK expression,and the effect of low level of FAK on cross reaction,cell invasion and proliferation were testified.Results Expressions of total ERK,FAK and p130cas had no significant change before and after stimulation.After stimulation with Fn,tyrosine phosphorylated ERK increased 2.90 times(P<0.05);cell invasiveness enhanced 2.36 times(P<0.05);and MTT value at 24 h increased 1.68 times(P<0.05).After stimulation with EGF,phosphorylated FAK(Y397) increased 2.75 times(P<0.05);phosphorylated p130cas(Y410) increased 4.33 times(P<0.05);cell invasiveness increased 1.50 times(P<0.05);and MTT value at 24 h increased 1.76 times(P<0.05).In cells transfected with FAK siRNA,FAK(Y397) phosphorylation was only 0.30 times of the control(P<0.05).After stimulation with Fn,ERK tyrosine phosphorylation was only 0.66 times of the control(P<0.05);cell invasiveness was only 0.37 of the control(P<0.05);and MTT value at 24 h was only 0.63 times of the control(P<0.05).After stimulation with EGF,p130(Y410) phosphorylation was only 0.49 times of the control(P<0.05);cell invasiveness was only 0.48 times of the control(P<0.05);and MTT value at 24 h was only 0.77 times of the control(P<0.05).Conclusion There is a crosstalk between EGFR and integrin signaling pathways in human gastric cancer cell SGC7901.FAK,which is a key module in the crosstalk,its inhibition can reduce invasion and proliferation of human gastric cancer cells induced by crosstalk between EGFR and integrin.
Keywords:gastric cancer  epidermal growth factor  integrin  crosstalk  invasion
本文献已被 CNKI 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号